Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Hemostemix Inc V.HEM

Alternate Symbol(s):  HMTXF

Hemostemix Inc. is a Canada-based clinical-stage biotechnology company. The Company’s principal business is to develop, manufacture and commercialize blood-derived stem cell therapies to treat various diseases. It is an autologous stem cell therapeutics company that holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01 is a lead clinical-stage candidate, like NCP-01 and CCP-01, is generated from the patient’s blood. The Company is engaged in providing treatment for ischemia, such as ischemic cardiomyopathy, angina, peripheral arterial disease including critical limb ischemia. The Company’s proprietary technology is a personalized regenerative therapy that is administered to a patient within seven days of the initial blood draw. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd., and PreCerv Inc.


TSXV:HEM - Post by User

Comment by milstogoon Dec 05, 2020 5:23pm
233 Views
Post# 32044690

RE:RE:RE:RE:RE:RE:Looks good to me

RE:RE:RE:RE:RE:RE:Looks good to me That's what it looks like. Then Makofka counldn't resist the opportunity to climb on board with Wood and fleece the very company he's CEO of. IMO what a couple of slimballs if that's what it is. At the very least one would think it'd be a conflict of interest. 

One thing we do know for sure though; if those two wanted the company that badly and went to such lengths to take it over these past four years then it's got to be one heck of a proven technology and one that will definately empact the whole health field. What a difference it'll make for so many people's lives.. 

Lets just hope the Judge sees it in Hemostemix's favor. As the saga continues...
<< Previous
Bullboard Posts
Next >>